Benchmark analyst Robert Wasserman downgraded Alterity Therapeutics (ATHE) to Hold from Speculative Buy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics price target raised to $12 from $8 at Maxim
- Alterity Therapeutics announces ATH434 Phase 2 trial results
- Alterity Therapeutics Ltd (ADR) trading halted, news pending
- Alterity Therapeutics reports cash balance of A$4.54M as of December 31
- Alterity Therapeutics Expands ASX Quoted Securities
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue